Brief: Mesoblast Says US FDA Supports Accelerated Approval Pathway For Rexlemestrocel-L
10/03/2024 22:59
March 11 (Reuters) - Mesoblast Ltd MSB.AX :
* US FDA SUPPORTS ACCELERATED APPROVAL PATHWAY FOR
REXLEMESTROCEL-L
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M